BMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)November 19, 2024 11:07 AM Neurogene (NGNE) PT Lowered to $46 at BairdNovember 19, 2024 7:26 AM Neurogene (NGNE) Reports In-Line Q3 EPSNovember 19, 2024 3:50 AM Form 10-Q Neurogene Inc. For: Sep 30November 18, 2024 5:28 PM Form 8-K Neurogene Inc. For: Nov 18November 18, 2024 5:26 PM Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNovember 18, 2024 5:25 PM Form 8-K Neurogene Inc. For: Nov 18November 18, 2024 6:51 AM Neurogene (NGNE) Provides Update on NGN-401 Gene Therapy TrialNovember 18, 2024 6:45 AM Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNovember 18, 2024 6:45 AM